Vaccine lot to vaccine lot comparison by consistency testing
VAC2VAC logo


Start Date
End Date
IMI2 - Call 3
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
7 850 000
EFPIA in kind
8 128 429
312 500
Total Cost
16 290 929


Developing and validating alternative, non-animal testing approaches for both human and veterinary vaccines is the main goal of the VAC2VAC project. In routine vaccine production, the current quality control approach requires large numbers of laboratory animals. VAC2VAC aims to provide data to support the ‘consistency approach’ for quality control that promotes the use of in vitro, analytical, non-animal based systems. The project brings together scientists from both the human and veterinary pharmaceutical industry along with academia and regulators. Together they plan to develop and validate non-animal tests; generate vaccine specific toolkits of consistency tests; increase our scientific understanding of vaccine quality; and contribute to the regulatory acceptance and routine use of non-animal tests during vaccine quality control testing.

Participants Show participants on map

EFPIA companies
  • Boehringer Ingelheim Vetmedica GMBH, Ingelheim am Rhein, Germany
  • Glaxosmithkline Biologicals SA, Rixensart, Belgium
  • Intervet International BV, Boxmeer, Netherlands
  • Merial SAS, Lyon, France
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi Pasteur SA, Lyon, France
  • Zoetis Belgium SA, Louvain la Neuve, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands
  • Ages - Osterreichische Agentur Fur Gesundheit Und Ernahrungssicherheit GMBH, Vienna, Austria
  • Association Internationale De Standardisation Biologique Pour L'Europe(Iabs-Eu), Lyon, France
  • Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany
  • Department of Health, Leeds, United Kingdom
  • European Commission - Directorate General Joint Research Centre - JRC, Brussels, Belgium
  • European Vaccine Initiative - EEIG, Heidelberg, Germany
  • Institut Scientifique De Sante Publique, Brussels, Belgium
  • Istituto Superiore Di Sanita, Roma, Italy
  • Ministerie Van Volksgezondheid, Welzijn En Sport, Bilthoven, Netherlands
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Sciensano, Brussels, Belgium
  • Stichting Biomedical Primate Research Center, Rijswijk, Netherlands
  • Stichting Hogeschool Utrecht, Utrecht, Netherlands
  • Universiteit Utrecht, Utrecht, Netherlands
Project leader
Sylvie Uhlrich
Sanofi Pasteur